NCT00464633 - Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Leukemia, Lymphocytic, Chronic

Interventions

DRUG

alvocidib

"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."

Trial Locations (34)

1000

Sanofi-Aventis Investigational Site Number 056001, Brussels

2065

Sanofi-Aventis Investigational Site Number 036001, St Leonards

3000

Sanofi-Aventis Investigational Site Number 056003, Leuven

5530

Sanofi-Aventis Investigational Site Number 056002, Yvoir

8000

Sanofi-Aventis Investigational Site Number 056006, Bruges

9000

Sanofi-Aventis Investigational Site Number 056004, Ghent

10021

Sanofi-Aventis Investigational Site Number 840005, New York

19104

Sanofi-Aventis Investigational Site Number 840020, Philadelphia

20132

Sanofi-Aventis Investigational Site Number 380001, Milan

24116

Sanofi-Aventis Investigational Site Number 276004, Kiel

27710

Sanofi-Aventis Investigational Site Number 840003, Durham

37044

Sanofi-Aventis Investigational Site Number 250002, Tours

40138

Sanofi-Aventis Investigational Site Number 380002, Bologna

43210

Sanofi-Aventis Investigational Site Number 840002, Columbus

44106

Sanofi-Aventis Investigational Site Number 840018, Cleveland

46202

Sanofi-Aventis Investigational Site Number 840017, Indianapolis

50937

Sanofi-Aventis Investigational Site Number 276001, Cologne

60611

Sanofi-Aventis Investigational Site Number 840010, Chicago

60637

Sanofi-Aventis Investigational Site Number 840012, Chicago

69495

Sanofi-Aventis Investigational Site Number 250003, Pierre-Bénite

75651

Sanofi-Aventis Investigational Site Number 250001, Paris

89081

Sanofi-Aventis Investigational Site Number 276002, Ulm

92103

Sanofi-Aventis Investigational Site Number 840008, San Diego

94143

Sanofi-Aventis Investigational Site Number 840022, San Francisco

02115

Sanofi-Aventis Investigational Site Number 840001, Boston

48109-0759

Sanofi-Aventis Investigational Site Number 840023, Ann Arbor

10029-6574

Sanofi-Aventis Investigational Site Number 840006, New York

1081 HV

Sanofi-Aventis Investigational Site Number 528003, Amsterdam

9713 GZ

Sanofi-Aventis Investigational Site Number 528001, Groningen

3015 CE

Sanofi-Aventis Investigational Site Number 528002, Rotterdam

00927

Sanofi-Aventis Investigational Site Number 630001, San Juan

AB25 2ZN

Sanofi-Aventis Investigational Site Number 826005, Aberdeen

B9 5SS

Sanofi-Aventis Investigational Site Number 826002, Birmingham

BH7 7DW

Sanofi-Aventis Investigational Site Number 826004, Bournemouth